Cargando…

Combination of ruthenium(II)-arene complex [Ru(η(6)-p-cymene)Cl(2)(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity

Ruthenium-based compounds show strong potential as anti-cancer drugs and are being investigated as alternatives to other well-established metal-based chemotherapeutics. The organometallic compound [Ru(η(6)-p-cymene)Cl(2)(pta)], where pta = 1,3,5-triaza-7-phosphaadamantane (RAPTA-C) exhibits broad ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berndsen, Robert H., Weiss, Andrea, Abdul, U. Kulsoom, Wong, Tse J., Meraldi, Patrick, Griffioen, Arjan W., Dyson, Paul J., Nowak-Sliwinska, Patrycja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320450/ https://www.ncbi.nlm.nih.gov/pubmed/28223694 http://dx.doi.org/10.1038/srep43005

Ejemplares similares

Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy
por: Weiss, Andrea, et al.
Publicado: (2015)

Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds
por: Kljun, Jakob, et al.
Publicado: (2023)

Dichlorido(η(6)-p-cymene)(ethoxydiphenylphosphane)ruthenium(II)
por: Knapp, Spring M. M., et al.
Publicado: (2012)

Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
por: Weiss, Andrea, et al.
Publicado: (2015)

Dichlorido(η(6)-p-cymene)(4-fluoroaniline-κN)ruthenium(II)
por: Sykora, Richard E., et al.
Publicado: (2010)

Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization
por: Weiss, Andrea, et al.
Publicado: (2014)

Physicochemical Studies and Anticancer Potency of Ruthenium η(6)-p-Cymene Complexes Containing Antibacterial Quinolones
por: Kljun, Jakob, et al.
Publicado: (2011)

(η(6)-p-Cymene)bis(trichloridostannyl)(triethoxyphosphine-κP)ruthenium(II)
por: Shapovalov, Sergey S., et al.
Publicado: (2009)

Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2012)

Facile Arene Ligand Exchange in p-Cymene Ruthenium(II) Complexes of Tertiary P-Chiral Ferrocenyl Phosphines
por: Popp, John, et al.
Publicado: (2019)

Dichlorido(η(6)-p-cymene)[tris(4-methoxyphenyl)phosphane]ruthenium(II)
por: Davis, Wade L., et al.
Publicado: (2021)

Crystal structure of [3-amino-2-(phenyldiazenyl)pyridine]chlorido(η(6)-p-cymene)ruthenium(II) chloride
por: Hansongnern, Kanidtha, et al.
Publicado: (2015)

p-Cymene Complexes of Ruthenium(II) as Antitumor Agents
por: Pujante-Galián, María Angeles, et al.
Publicado: (2020)

μ-Pyrazine-2,5-dicarboxylato-bis[chlorido(η(6)-p-cymene)ruthenium(II)] tert-butanol disolvate
por: Sanchez Ballester, Noelia M., et al.
Publicado: (2008)

Angiostatic vaccines, an underestimated approach of cancer therapy
por: Griffioen, Arjan W.
Publicado: (2014)

A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7)
por: van Beijnum, Judy R., et al.
Publicado: (2017)

Ruthenium(II)(η(6)-arene) Complexes of Thiourea Derivatives: Synthesis, Characterization and Urease Inhibition
por: Hanif, Muhammad, et al.
Publicado: (2014)

Light Triggers the Antiproliferative Activity of Naphthalimide-Conjugated (η(6)-arene)ruthenium(II) Complexes
por: Bisceglie, Franco, et al.
Publicado: (2022)

Altered DNA Binding and Amplification of Human Breast Cancer Suppressor Gene BRCA1 Induced by a Novel Antitumor Compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)]
por: Chakree, Korawan, et al.
Publicado: (2012)

Computational evaluation of the η6-arene during the ATH of imines on Noyori’s RuII catalyst
por: Kacer, Petr, et al.
Publicado: (2014)

Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment
por: Nowak-Sliwinska, Patrycja, et al.
Publicado: (2018)

Anticancer and antimicrobial properties of novel η(6)-p-cymene ruthenium(ii) complexes containing a N,S-type ligand, their structural and theoretical characterization
por: Namiecińska, Ewelina, et al.
Publicado: (2019)

Tetraethylammonium trichlorido(η(6)-p-cymene)ruthenate(II)
por: Wu, Fang-Hui, et al.
Publicado: (2009)

Ruthenium(η(6),η(1)-arene-CH(2)-NHC) Catalysts for Direct Arylation of 2-Phenylpyridine with (Hetero)Aryl Chlorides in Water
por: Kaloğlu, Nazan, et al.
Publicado: (2018)

Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib
por: Berndsen, Robert H., et al.
Publicado: (2019)

Ru(ii)arene(N^N bpy/phen)-based RAPTA complexes for in vitro anti-tumour activity in human glioblastoma cancer cell lines and in vivo toxicity studies in a zebrafish model
por: P. K., Anuja, et al.
Publicado: (2022)

Di-μ-nitrosyl-bis[(η(5)-pentamethylcyclopentadienyl)ruthenium(0)](Ru—Ru). Corrigendum
por: Pearsal, Matthew, et al.
Publicado: (2010)

(R,R (Fc),S (Ru))-Chlorido(η(6)-p-cymene){1-[1-(diphenylphosphanyl)ethyl]-2-[2-(diphenylphosphanyl)phenyl]ferrocene-κ(2) P,P′}ruthenium(II) hexafluoridophosphate
por: Schuecker, Raffael, et al.
Publicado: (2011)

NF-κB: a new player in angiostatic therapy
por: Tabruyn, Sebastien P., et al.
Publicado: (2008)

Novel Ruthenium-Silver PTA-Based Polymers and Their Behavior in Water
por: Sierra-Martin, Benjamin, et al.
Publicado: (2019)

The Significant Influence of a Second Metal on the Antiproliferative Properties of the Complex [Ru(η(6)−C(10)H(14))(Cl(2))(dmoPTA)]
por: Kordestani, Nazanin, et al.
Publicado: (2021)

Asymmetric transfer hydrogenation of imines and ketones using chiral Ru(II)Cl(η(6)-p-cymene)[(S,S)-N-TsDPEN] catalyst: a computational study
por: Kačer, Petr, et al.
Publicado: (2012)

Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action
por: Babak, Maria V., et al.
Publicado: (2015)

Synthesis and Characterization of New Ruthenium (II) Complexes of Stoichiometry [Ru(p-Cymene)Cl(2)L] and Their Cytotoxicity against HeLa-Type Cancer Cells
por: Fuster, Marta G., et al.
Publicado: (2022)

Ligand substitutions between ruthenium–cymene compounds can control protein versus DNA targeting and anticancer activity
por: Adhireksan, Zenita, et al.
Publicado: (2014)

Chemistry of a novel zerovalent ruthenium π-acidic alkene complex, Ru (η(6)-1,3,5-cyclooctatriene)(η(2)-dimethyl fumarate)(2)
por: Mitsudo, Take-aki, et al.
Publicado: (2007)

Erratum: Berndsen, R.H., et al. Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib, Cancers 2019, 11, 1878
por: Berndsen, Robert H., et al.
Publicado: (2020)

(2,2′-Bipyridyl)(η(6)-p-cymene)iodidoruthenium(II) hexafluoridophosphate
por: Kelani, Monsuru T., et al.
Publicado: (2023)

Opportunities Offered by Chiral η(6)-Arene/N-Arylsulfonyl-diamine-Ru(II) Catalysts in the Asymmetric Transfer Hydrogenation of Ketones and Imines
por: Václavík, Jiří, et al.
Publicado: (2011)

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition
por: Nowak-Sliwinska, P, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vb7auqfbkaijless6l48anh0p2